ADC Therapeutics (ADCT) reported Loss for third quarter that Decreased from last year and beat the Street estimates.
The company's bottom line came in at -$40.97 million, or -$0.30 per share. This compares with -$43.97 million, or -$0.42 per share, last year.
Excluding items, ADC Therapeutics reported adjusted earnings of -$25.52 million or -$0.19 per share for the period.
Analysts on average had expected the company to earn -$0.36 per share. Analysts' estimates typically exclude special items.
The company's revenue for the period fell 11.0% to $16.43 million from $18.46 million last year.
ADC Therapeutics earnings at a glance (GAAP) :
-Earnings: -$40.97 Mln. vs. -$43.97 Mln. last year.-EPS: -$0.30 vs. -$0.42 last year.-Revenue: $16.43 Mln vs. $18.46 Mln last year.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.